Mouse Models for Human Cancer Unit


Lab Location: #3-17   Email:   Tel: 65869836

Vinay Tergaonkar obtained his Ph.D. (2001), from National Center for Biological Sciences, Bangalore. During his graduate studies he was awarded an international cancer society (UICC) fellowship for collaborative research at Tufts University, Boston, USA. He has been a fellow (2001-2004) and a special fellow (2004-present) of the Leukemia and Lymphoma Society of America and conducted his postdoctoral studies at the Salk Institute for Biological Studies, La Jolla, California. He joined IMCB in late 2005 as Principal Investigator (Assistant professor) and became a Senior Principal Investigator (Associate professor) in 2010 and Research Director (Professor) in 2015.

He holds adjunct appointments at 1) Department of Biochemistry (NUS) 2) Cancer Science Institute, 3) Singapore Eye Research Institute and 4) National Cancer Centre, Singapore. He has been invited to speak at various international venues and meetings such as the Barossa and Hunter valley meetings in Australia, Genes and Cancer meeting in UK, The Argentine Pharmacological society meeting in Buenos Aires, Aichi and Japanese Cancer Society meetings in Japan and the Keystone Symposia. He serves on Editorial Boards of 1) Science Advances, 2) Molecular and Cellular Biology (American Society for Microbiology), 3) Biochemical Journal (Portland Press) 4) Critical Reviews in Oncology/Hematology (Elsevier Press), 5) BMC Research Notes (Biomed Central) and 6) Telomeres and Telomerase. He has received international recognition for his work including the British council development award (2014) and the Premier's fellowship from Government of South Australia (2015)




Mouse models of human cancer unit

About Us

Mouse Models of Human Cancer is a uniquely positioned unit in Institute of Molecular and Cell Biology (IMCB) that provides comprehensive drug discovery platform to academic and Pharmaceutical industry. We have a strong talent pool of scientists from both academic and industrial background. Our capabilities span from specific solutions to integrated discovery projects across multiple therapeutic areas with specific focus on Cancer, Inflammation, Autoimmune & Metabolic Disorders.

We are positioned to engage or address any drug discovery concepts, issues, opportunities, questions or challenges by performing structured and thorough drug discovery programmes from target validation to preclinical discovery. Please get in touch with us if you would like to work with our world class team of experts and innovative technology platforms for initial phases of drug discovery.

Our research capabilities include:

For Contact:

Manikandan Lakshmanan

Mouse Models of Human Cancer

Institute of Molecular & Cell Biology

Proteos Building

61 Biopolis Drive

Singapore 138673

Tel: (65) 65869710




Department: Vinay- TERGAONKAR

Name: Manickam ARUN KUMAR

Designation: Senior Research Fellow


Name: Ern Yu TAN

Designation: Clinician Scientist


Name: Venkataramanan RAMADASS

Designation: Lead Medicinal Chemist


Name: Anandhkumar RAJU

Designation: Research Officer



Our Team



Yinghui Li, Qi-Ling Zhou, Wenjie Sun, Prashant Chandrasekharan, Hui Shan Cheng, Zhe Ying, Manikandan Lakshmanan, Anandhkumar Raju, Daniel G. Tenen, Shi-Yuan Cheng, Kai-Hsiang Chuang, Jun Li, Shyam Prabhakar, Mengfeng Li, Vinay Tergaonkar.
Non-canonical NF-κB signalling and ETS1/2 co-operatively drive C250T mutant TERT promoter activation.
Nature Cell Biology (In Press).

S Sayan Chakraborty, Manikandan Lakshmanan, Hannah L. F. Swa, Jianxiang Chen, Xiaoqian Zhang, Yan Shan Ong, Li Shen Loo, Semih Can Akıncılar, Jayantha Gunaratne, Vinay Tergaonkar, Kam M. Hui and Wanjin Hong.
An oncogenic role of Agrin in regulating focal adhesion dynamics in Hepatocellular carcinoma.
Nature Communications 2015 29;6:6184

Yan B, Kuick CH, Lim M, Venkataraman K, Tennakoon C, Loh E, Lian D, Leong MY, Lakshmanan M, Tergaonkar V, Sung WK, Soh SY, Chang KT.
Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
PLoS One. 2014; 9(9):e106575.

Qiu B, Shi X, Wong ET, Lim J, Bezzi M, Low D, Zhou Q, Akıncılar SC, Lakshmanan M, Swa HL, Tham JM, Gunaratne J, Cheng KK, Hong W, Lam KS, Ikawa M, Guccione E, Xu A, Han W, Tergaonkar V.
NUCKS is a positive transcriptional regulator of insulin signaling.
Cell Rep. 2014 Jun 26;7(6):1876-86

Ghosh A, Saginc G, Leow SC, Khattar E, Shin EM, Yan TD, Wong M, Zhang Z, Li G, Sung WK, Zhou J, Chng WJ, Li S, Liu E, Tergaonkar V. (2012).
Telomerase directly regulates NF-κB-dependent transcription.
Nature Cell Biology (article) 2012 Dec;14(12):1270-81. doi: 10.1038/ncb2621. Epub 2012 Nov 18.

Zhao-Hui Wu, Ee Tsin Wong, Yuling Shi, Zhijian Chen, Shigeki Miyamoto and Vinay Tergaonkar. (2010).
ATM-dependent ELKS ubiquitination coordinates IKK activation in response to genotoxic stress.
Molecular Cell. ;40(1):75-86.

Ghosh,  and VInay Tergaonkar. (2010).
Telomeres and inflammation: Rap1 joins the ends?
Cell Cycle. 9(19):3834-5.

Hsiangling Teo, Sourav Ghosh , Hendrik Luesch , Ee Tsin Wong, Arkasubhra Ghosh, Najib Malik, Anthony Orth, Paul de Jesus, Anthony S Perry, Jeffrey D. Oliver, Nhan L. Tran, Lisa J. Speiser, Enrique Saez,  Peter Schultz, Sumit Chanda, Inder M Verma and Vinay Tergaonkar. (2010).
Telomere independent Rap1 is an IKK-adaptor and regulates NFkB- dependent gene expression.
Nature Cell Biology (article). 12(8):758-67.
Covered by local and international press.

Tergaonkar V. (2009).
p53 and NFkappaB: fresh breath in the cross talk.
Cell Research. 19 (12), 1313-5.

Susila A, Chan H, Loh AX, Phang HQ, Wong ET, Tergaonkar V, Koh CG. (2010).
The POPX2 phosphatase regulates cancer cell motility and invasiveness.
Cell Cycle. 9(1), 179-87.

Sethi G, Tergaonkar V. (2009).
Potential pharmacological control of the NF-kappaB pathway.
Trends in Pharmacological Sciences. 30(6), 313-21.

Chew J, Biswas S, Shreeram S, Humaidi M, Wong ET, Dhillion MK, Teo H, Hazra A, Fang CC, López-Collazo E, Bulavin DV, Tergaonkar V. (2009).
WIP1 phosphatase is a negative regulator of NF-kappaB signalling.
Nature Cell Biology. 11(5), 659-66.
Covered by local and international press.

Shen HM, Tergaonkar V. (2009).
NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy.
Apoptosis. 14(4), 348-63.

Wong ET, Tergaonkar V. (2009).
Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clinical Science (Lond). 116(6), 451-65.

Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB*, Verma IM. (2009). Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci U S A. 106(8), 2629-34. * Corresponding Author

Singh K, Sinha S, Malonia SK, Bist P, Tergaonkar V, Chattopadhyay S. (2009).
Tumor suppressor SMAR1 represses IkappaBalpha expression and inhibits p65 transactivation through matrix attachment regions.
J Biol Chem. 284(2), 1267-78.

Dey A, Tergaonkar V*, Lane DP. (2008).
Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.
Nature Reviews Drug Discovery. 7(12), 1031-40. * Corresponding Author

Dey A, Wong E, Kua N, Teo HL, Tergaonkar V*, Lane D. (2008).
Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy.
Cell Cycle. 7(23), 3759-67.
* Corresponding Author

Lee KG, Xu S, Wong ET, Tergaonkar V, Lam KP. (2008).
Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells.
J Biol Chem. 283(17), 11189-98.

Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M,
Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J. (2007).
 IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.
Cell. 131(4), 682-93.

Dey A, Wong ET, Cheok CF, Tergaonkar V*, Lane DP. (2008).
R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.
Cell Death Differ. 15(2), 263-73. *Corresponding Author

Irelan JT, Murphy TJ, DeJesus PD, Teo H, Xu D, Gomez-Ferreria MA, Zhou Y, Miraglia LJ, Rines DR, Verma IM, Sharp DJ, Tergaonkar V, Chanda SK. (2007).
A role for IkappaB kinase 2 in bipolar spindle assembly.
Proc Natl Acad Sci U S A. 104(43), 16940-5.

Ang HL, Tergaonkar V. (2007).
Notch and NFkappaB signaling pathways: Do they collaborate in normal vertebrate brain development and function? Notch and NFkappaB signaling pathways: Do they collaborate in normal vertebrate brain development and function?
Bioessays. 29(10), 1039-47.

Dey A, Wong ET, Bist P, Tergaonkar V, Lane DP. (2007).
Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.
Cell Cycle. 6(17), 2178-85.

Biswas SK, Bist P, Dhillon MK, Kajiji T, Del Fresno C, Yamamoto M, Lopez-Collazo E, Akira S, Tergaonkar V. (2007).
Role for MyD88-independent, TRIF pathway in lipid A/TLR4-induced endotoxin tolerance.
Journal of Immunology. 179(6), 4083-92.

Biswas SK, Tergaonkar V. (2007).
Myeloid differentiation factor 88-independent Toll-like receptor pathway: Sustaining inflammation or promoting tolerance?
Int J Biochem Cell Biol. 39(9), 1582-92.

Tergaonkar V*, Perkins ND. (2007).
p53 and NF-kappaB crosstalk: IKKalpha tips the balance.
Molecular Cell. 26(2), 158-9. *Corresponding author.

Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A. (2007).
A fourth IkappaB protein within the NF-kappaB signaling module.
Cell. 128(2), 369-81.

Ghosh S, Tergaonkar V*, Rothlin CV, Correa RG, Bottero V, Bist P, Verma IM, Hunter T. (2006).
Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival.
Cancer Cell. 10(3), 215-26. *Co-first author

Tergaonkar V. (2006).
NFkappaB pathway: a good signaling paradigm and therapeutic target.
Int J Biochem Cell Biol. 38(10), 1647-53.